<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CEFAZOLIN- cefazolin sodium injection, powder, for solution </strong><br>Sagent Pharmaceuticals<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Cefazolin for Injection, USP safely and effectively. See full prescribing information for Cefazolin for Injection, USP.<br>CEFAZOLIN FOR INJECTION, USP for intravenous use<br>Initial U.S. Approval: 1973
</div>
<div>
<div><p class="Highlighta">To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria. (<a href="#s51">12.4</a>)
 </p></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Cefazolin for Injection, USP is a cephalosporin antibacterial indicated in the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible isolates of the designated microorganisms: <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> (<a href="#s3">1.1</a>); <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> (<a href="#s4">1.2</a>); skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<a href="#s5">1.3</a>); biliary tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<a href="#s6">1.4</a>); bone and <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">joint infections</span> (<a href="#s7">1.5</a>); <span class="product-label-link" type="condition" conceptid="4193988" conceptname="Genital infection">genital infections</span> (<a href="#s8">1.6</a>); <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span> (<a href="#s9">1.7</a>); <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> (<a href="#s10">1.8</a>) and perioperative prophylaxis (<a href="#s11">1.9</a>).
 </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">For intravenous use only over approximately 30 minutes. (<a href="#s12">2</a>)
 </p>
<table width="100%">
<col align="left" width="36.821%">
<col align="left" width="31.589%">
<col align="left" width="31.589%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="Footnote Highlighta">* In rare instances, doses of up to 12 grams of cefazolin per day have been used.
 </p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="left" colspan="3" valign="middle"><span class="Bold">Recommended Dosing Schedule in Adult Patients with CrCl Greater Than or Equal To 55 mL/min. (<a href="#s13">2.1</a>)</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<span class="Bold">Site and Type of</span><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span>
</td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Dose</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Frequency</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Moderate to severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">500 mg to 1 gram
</td>
<td class="Botrule Rrule" align="center" valign="middle">every 6 to 8 hours
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Mild <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible gram-positive cocci
</td>
<td class="Botrule Rrule" align="center" valign="middle">250 mg to 500 mg
</td>
<td class="Botrule Rrule" align="center" valign="middle">every 8 hours
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Acute, uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 gram
</td>
<td class="Botrule Rrule" align="center" valign="middle">every 12 hours
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="258785" conceptname="Pneumococcal pneumonia">Pneumococcal pneumonia</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">500 mg
</td>
<td class="Botrule Rrule" align="center" valign="middle">every 12 hours
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Severe, life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (e.g., <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>)*
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 gram to 1.5 grams
</td>
<td class="Botrule Rrule" align="center" valign="middle">every 6 hours
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Perioperative prophylaxis
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 gram to 2 grams
</td>
<td class="Botrule Rrule" align="center" valign="middle">½ to 1 hour prior to start of surgery
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">500 mg to 1 gram
</td>
<td class="Botrule Rrule" align="center" valign="middle">during surgery for lengthy procedures
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">500 mg to 1 gram
</td>
<td class="Botrule Rrule" align="center" valign="middle">every 6 to 8 hours for 24 hours postoperatively
</td>
</tr>
</tbody>
</table>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">10 grams per Pharmacy Bulk Package (<a href="#s23">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (<a href="#s25">4.1</a>)
 </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>: Cross-<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> may occur in up to 10% of patients with a history of <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">penicillin allergy</span>. If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> occurs, discontinue the drug. (<a href="#s27">5.1</a>)
</li>
<li>Use in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>: Dose adjustment required for patients with CrCl less than 55 mL/min. (<a href="#s28">5.2</a>)
</li>
<li>
<span class="Italics">Clostridium difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>: May range from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Evaluate if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs. (<a href="#s29">5.3</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc"><li>Most common adverse reactions: gastrointestinal (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>), and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>). (<a href="#s34">6</a>)
</li></ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals, Inc. at 1-866-625-1618 or FDA at 1-800-FDA-1088 or </span><span class="Bold Underline">www.fda.gov/medwatch</span><span class="Bold">.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc"><li>Probenecid: may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood concentrations. (<a href="#s37">7</a>)
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Pediatric use: Safety and effectiveness for use in premature infants and neonates have not been established. See Dosage and Administration (<a href="#s16">2.4</a>) for recommended dosage in pediatric patients older than 1 month (<a href="#s43">8.4</a>).
</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>: Lower daily dosage of Cefazolin for Injection is required in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (creatinine clearance less than 55 mL/min.) (<a href="#s45">8.6</a>)
</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 2/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-2" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h2><a href="#section-2.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory Tract Infections</span>
</a></h2>
<h2><a href="#section-2.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span>
</a></h2>
<h2><a href="#section-2.3" class="toc">1.3 Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>
</a></h2>
<h2><a href="#section-2.4" class="toc">1.4 Biliary Tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>
</a></h2>
<h2><a href="#section-2.5" class="toc">1.5 Bone and <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">Joint Infections</span>
</a></h2>
<h2><a href="#section-2.6" class="toc">1.6 <span class="product-label-link" type="condition" conceptid="4193988" conceptname="Genital infection">Genital Infections</span>
</a></h2>
<h2><a href="#section-2.7" class="toc">1.7 <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Septicemia</span>
</a></h2>
<h2><a href="#section-2.8" class="toc">1.8 <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span>
</a></h2>
<h2><a href="#section-2.9" class="toc">1.9 Perioperative Prophylaxis
</a></h2>
<h1><a href="#section-3" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-3.1" class="toc">2.1 Adult Population
</a></h2>
<h2><a href="#section-3.2" class="toc">2.2 Perioperative <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Use
</a></h2>
<h2><a href="#section-3.3" class="toc">2.3 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-3.4" class="toc">2.4 Pediatric Dosage
</a></h2>
<h2><a href="#section-3.5" class="toc">2.5 Preparation for Use of Cefazolin for Injection
</a></h2>
<h1><a href="#section-4" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-5" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to Cefazolin or the Cephalosporin Class of Antibacterial Drugs, Penicillins, or Other Beta-lactams
</a></h2>
<h1><a href="#section-6" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> to Cefazolin, Cephalosporins, Penicillins, or Other Beta-lactams
</a></h2>
<h2><a href="#section-6.2" class="toc">5.2 Use In Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-6.3" class="toc">5.3 <span class="Italics">Clostridium difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</a></h2>
<h2><a href="#section-6.4" class="toc">5.4 Risk of Development of Drug-resistant Bacteria
</a></h2>
<h2><a href="#section-6.5" class="toc">5.5 Drug/Laboratory Test Interactions
</a></h2>
<h1><a href="#section-7" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">6.1 Clinical Trials Experience
</a></h2>
<h2><a href="#section-7.2" class="toc">6.2 Cephalosporin-class Adverse Reactions
</a></h2>
<h1><a href="#section-8" class="toc">7 DRUG INTERACTIONS
</a></h1>
<h1><a href="#section-9" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-9.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-9.2" class="toc">8.2 Labor and Delivery
</a></h2>
<h2><a href="#section-9.3" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-9.4" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-9.5" class="toc">8.5 Geriatric Use
</a></h2>
<h2><a href="#section-9.6" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h1><a href="#section-10" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics
</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics
</a></h2>
<h2><a href="#section-11.4" class="toc">12.4 Microbiology
</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-13" class="toc">15 REFERENCES
</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<table width="100%">
<col align="left" width="100.000%">
<tbody class="Headless">
<tr class="First"><td class="Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">PHARMACY BULK PACKAGE –</span></td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">NOT FOR DIRECT INFUSION</span></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
</p>
<p>Cefazolin for Injection, USP is indicated for the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> when caused by susceptible bacteria.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-2.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory Tract Infections</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> due to <span class="Italics">Streptococcus pneumoniae, Staphylococcus aureus</span> and <span class="Italics">Streptococcus pyogenes</span>.
</p>
<p>Injectable benzathine penicillin is considered the drug of choice in treatment and prevention of <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>, including the prophylaxis of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>.
</p>
<p>Cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> are not available.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-2.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infections</span> due to <span class="Italics">Escherichia coli,</span> and <span class="Italics">Proteus mirabilis</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-2.3"></a><p></p>
<h2>1.3 Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>
</h2>
<p class="First">Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">S. aureus</span>, <span class="Italics">S. pyogenes</span>, and <span class="Italics">Streptococcus agalactiae</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-2.4"></a><p></p>
<h2>1.4 Biliary Tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>
</h2>
<p class="First">Biliary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">E. coli</span>, various isolates of streptococci, <span class="Italics">P. mirabilis,</span> and <span class="Italics">S. aureus</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-2.5"></a><p></p>
<h2>1.5 Bone and <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">Joint Infections</span>
</h2>
<p class="First">Bone and <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">joint infections</span> due to <span class="Italics">S. aureus</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-2.6"></a><p></p>
<h2>1.6 <span class="product-label-link" type="condition" conceptid="4193988" conceptname="Genital infection">Genital Infections</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4193988" conceptname="Genital infection">Genital infections</span> due to <span class="Italics">E. coli,</span> and <span class="Italics">P. mirabilis.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-2.7"></a><p></p>
<h2>1.7 <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Septicemia</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Septicemia</span> due to <span class="Italics">S. pneumoniae, S. aureus</span>, <span class="Italics">P. mirabilis,</span> and <span class="Italics">E. coli</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-2.8"></a><p></p>
<h2>1.8 <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span> due to <span class="Italics">S. aureus</span> and <span class="Italics">S. pyogenes.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-2.9"></a><p></p>
<h2>1.9 Perioperative Prophylaxis
</h2>
<p class="First">The <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> administration of cefazolin preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain <span class="product-label-link" type="condition" conceptid="437474" conceptname="Postoperative infection">postoperative infections</span> in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with <span class="product-label-link" type="condition" conceptid="194991" conceptname="Calculus of gallbladder with acute cholecystitis">acute cholecystitis</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">obstructive jaundice</span>, or common duct bile stones).
</p>
<p>The perioperative use of cefazolin may also be effective in surgical patients in whom <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty).
</p>
<p>If there are signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s12"></a><a name="section-3"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-3.1"></a><p></p>
<h2>2.1 Adult Population
</h2>
<p class="First">The recommended adult dosages are outlined in <a href="#t1">Table 1</a>. Cefazolin for Injection should be administered intravenously (IV) over approximately 30 minutes.
</p>
<p><span class="Bold">After constitution, cefazolin can be administered by parenteral administration. However, the intent of this pharmacy bulk package is for the preparation of the solutions for intravenous infusion only.</span></p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1: Recommended Dosing Schedule in Adult Patients with CrCl Greater Than or Equal To 55 mL/min.
</span></caption>
<col align="left" width="41.100%">
<col align="left" width="26.067%">
<col align="left" width="32.833%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote">* In rare instances, doses of up to 12 grams of cefazolin per day have been used.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle"><span class="Bold">Site and Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Dose</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Frequency</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Moderate to severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">500 mg to 1 gram
</td>
<td class="Botrule Rrule" align="center" valign="middle">every 6 to 8 hours
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Mild <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible gram-positive cocci
</td>
<td class="Botrule Rrule" align="center" valign="middle">250 mg to 500 mg
</td>
<td class="Botrule Rrule" align="center" valign="middle">every 8 hours
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Acute, uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 gram
</td>
<td class="Botrule Rrule" align="center" valign="middle">every 12 hours
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="258785" conceptname="Pneumococcal pneumonia">Pneumococcal pneumonia</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">500 mg
</td>
<td class="Botrule Rrule" align="center" valign="middle">every 12 hours
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">Severe, life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (e.g., <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>)*
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 gram to 1.5 grams
</td>
<td class="Botrule Rrule" align="center" valign="middle">every 6 hours
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-3.2"></a><p></p>
<h2>2.2 Perioperative <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Use
</h2>
<p class="First">To prevent <span class="product-label-link" type="condition" conceptid="437474" conceptname="Postoperative infection">postoperative infection</span> in contaminated or potentially contaminated surgery, recommended doses are:
</p>
<ul class="Disc">
<li>1 gram IV administered ½ hour to 1 hour prior to the start of surgery.
</li>
<li>For lengthy operative procedures (e.g., 2 hours or more), 500 mg to 1 gram IV during surgery (administration modified depending on the duration of the operative procedure).
</li>
<li>500 mg to 1 gram IV every 6 to 8 hours for 24 hours postoperatively.
</li>
</ul>
<p>It is important that (i) the preoperative dose be given just prior (1/2 hour to 1 hour) to the start of surgery so that adequate antibacterial concentrations are present in the serum and tissues at the time of initial surgical incision; and (ii) cefazolin be administered, if necessary, at appropriate intervals during surgery to provide sufficient concentrations of the antibacterial drug at the anticipated moments of greatest exposure to infective organisms.
</p>
<p>The <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> administration of cefazolin should usually be discontinued within a 24-hour period after the surgical procedure. In surgery where the occurrence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> administration of cefazolin may be continued for 3 to 5 days following the completion of surgery.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-3.3"></a><p></p>
<h2>2.3 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">Cefazolin may be used in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> with the dosage adjustments outlined in <a href="#t2">Table 2</a>. All reduced dosage recommendations apply after an initial loading dose appropriate to the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2: Dosage Adjustment for Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</span></caption>
<col align="left" width="45.918%">
<col align="left" width="20.760%">
<col align="left" width="33.322%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle"><span class="Bold">Creatinine Clearance</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Dose</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Frequency</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">55 mL/min. or greater
</td>
<td class="Botrule Rrule" align="center" valign="middle">full dose
</td>
<td class="Botrule Rrule" align="center" valign="middle">normal frequency
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">35 to 54 mL/min.
</td>
<td class="Botrule Rrule" align="center" valign="middle">full dose
</td>
<td class="Botrule Rrule" align="center" valign="middle">every 8 hours or longer
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">11 to 34 mL/min.
</td>
<td class="Botrule Rrule" align="center" valign="middle">1/2 usual dose
</td>
<td class="Botrule Rrule" align="center" valign="middle">every 12 hours
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">10 mL/min. or less
</td>
<td class="Botrule Rrule" align="center" valign="middle">1/2 usual dose
</td>
<td class="Botrule Rrule" align="center" valign="middle">every 18 to 24 hours
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-3.4"></a><p></p>
<h2>2.4 Pediatric Dosage
</h2>
<p class="First">In pediatric patients, a total daily dosage of 25 to 50 mg per kg (approximately 10 to 20 mg per pound) of body weight, divided into 3 or 4 equal doses, is effective for most mild to moderately severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Total daily dosage may be increased to 100 mg per kg (45 mg per pound) of body weight for severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Since safety for use in premature infants and in neonates has not been established, the use of Cefazolin for Injection in these patients is not recommended.
</p>
<p>In pediatric patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance of 70 to 40 mL/min.), 60 percent of the normal daily dose given in equally divided doses every 12 hours should be sufficient. In patients with moderate impairment (creatinine clearance of 40 to 20 mL/min.), 25 percent of the normal daily dose given in equally divided doses every 12 hours should be adequate. Pediatric patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance of 20 to 5 mL/min.) may be given 10 percent of the normal daily dose every 24 hours. All dosage recommendations apply after an initial loading dose.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-3.5"></a><p></p>
<h2>2.5 Preparation for Use of Cefazolin for Injection
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-3.5.1"></a><p></p>
<p class="First"><span class="Underline">Reconstitution</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-3.5.1.1"></a><p></p>
<p class="First"><span class="Italics">Preparation of Parenteral Solution</span></p>
<p>Parenteral drug products should be SHAKEN WELL when reconstituted, and inspected visually for particulate matter prior to administration. If particulate matter is evident in reconstituted fluids, the drug solutions should be discarded.
</p>
<p>Reconstituted solutions may range in color from <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow to yellow without a change in potency.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-3.5.1.2"></a><p></p>
<p class="First"><span class="Italics">Directions for Proper Use of a Pharmacy Bulk Package</span></p>
<p>Not for direct infusion. The Pharmacy Bulk Package is for use in the hospital pharmacy admixture service only in a suitable work area, such as a laminar flow hood. Using aseptic technique, the closure may be penetrated only one time using a suitable sterile dispensing set that allows measured dispensing of the contents. Use of a syringe and needle is not recommended as it may cause leakage. After entry, use entire contents of Pharmacy Bulk Package promptly. The entire contents of the Pharmacy Bulk Package should be dispensed within <span class="Bold">4 hours</span> of initial entry. This time limit should begin with the introduction of the solvent or diluent into the Pharmacy Bulk Package. Discard Pharmacy Bulk Package within <span class="Bold">4 hours</span> after initial entry.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-3.5.1.3"></a><p></p>
<p class="First"><span class="Italics">Pharmacy Bulk Packages</span></p>
<p>Add Sterile Water for Injection, Bacteriostatic Water for Injection or Sodium Chloride Injection according to the table below. SHAKE WELL.
</p>
<table width="100%">
<col align="left" width="28.425%">
<col align="left" width="20.725%">
<col align="left" width="26.375%">
<col align="left" width="24.475%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Pharmacy Bulk</span><br><span class="Bold">Package Size</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Amount of Diluent</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Approximate</span><br><span class="Bold">Concentration</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Approximate</span><br><span class="Bold">Available Volume</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">10 grams
</td>
<td class="Botrule Rrule" align="center" valign="top">45 mL
</td>
<td class="Botrule Rrule" align="center" valign="top">1 gram/5 mL
</td>
<td class="Botrule Rrule" align="center" valign="top">51 mL
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">10 grams
</td>
<td class="Botrule Rrule" align="center" valign="top">96 mL
</td>
<td class="Botrule Rrule" align="center" valign="top">1 gram/10 mL
</td>
<td class="Botrule Rrule" align="center" valign="top">102 mL
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-3.5.2"></a><p></p>
<p class="First"><span class="Underline">Administration</span></p>
<p><span class="Bold">Intermittent or continuous infusion</span>: Dilute reconstituted Cefazolin for Injection in 50 to 100 mL of one of the following solutions:
</p>
<dl>
<dt> 
</dt>
<dd>Sodium Chloride Injection, USP
</dd>
<dt> 
</dt>
<dd>5% or 10% Dextrose Injection, USP
</dd>
<dt> 
</dt>
<dd>5% Dextrose in Lactated Ringer's Injection, USP
</dd>
<dt> 
</dt>
<dd>5% Dextrose and 0.9% Sodium Chloride Injection, USP
</dd>
<dt> 
</dt>
<dd>5% Dextrose and 0.45% Sodium Chloride Injection, USP
</dd>
<dt> 
</dt>
<dd>5% Dextrose and 0.2% Sodium Chloride Injection, USP
</dd>
<dt> 
</dt>
<dd>Lactated Ringer's Injection, USP
</dd>
<dt> 
</dt>
<dd>Invert Sugar 5% or 10% in Sterile Water for Injection
</dd>
<dt> 
</dt>
<dd>Ringer's Injection, USP
</dd>
<dt> 
</dt>
<dd>5% Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> Injection, USP
</dd>
</dl>
<p>When diluted according to the instructions above, Cefazolin for Injection is stable for 24 hours at room temperature or for 10 days if stored under refrigeration (5°C or 41°F).
</p>
<p>Prior to administration parenteral drug products should be inspected visually for particulate matter and discoloration whenever solution and container permit.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s23"></a><a name="section-4"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">Cefazolin for Injection, USP is supplied in 10 grams Pharmacy Bulk Package.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s24"></a><a name="section-5"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-5.1"></a><p></p>
<h2>4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to Cefazolin or the Cephalosporin Class of Antibacterial Drugs, Penicillins, or Other Beta-lactams
</h2>
<p class="First">Cefazolin for Injection is contraindicated in patients who have a history of <span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">immediate hypersensitivity reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>) to cefazolin or the cephalosporin class of antibacterial drugs, penicillins, or other beta-lactams <span class="Italics">[see Warnings and Precautions (<a href="#s27">5.1</a>)]</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s26"></a><a name="section-6"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-6.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> to Cefazolin, Cephalosporins, Penicillins, or Other Beta-lactams
</h2>
<p class="First">Serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs. Before therapy with Cefazolin for Injection is instituted, careful inquiry should be made to determine whether the patient has had previous <span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">immediate hypersensitivity reactions</span> to cefazolin, cephalosporins, penicillins, or carbapenems. Exercise caution if this product is to be given to penicillin-sensitive patients because cross-<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> among beta-lactam antibacterial drugs has been clearly documented and may occur in up to 10% of patients with a history of <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">penicillin allergy</span>. If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to Cefazolin for Injection occurs, discontinue the drug.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-6.2"></a><p></p>
<h2>5.2 Use In Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">As with other beta-lactam antibacterial drugs, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> may occur if inappropriately high doses are administered to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (creatinine clearance less than 55 mL/min.) <span class="Italics">[see Dosage and Administration (<a href="#s15">2.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-6.3"></a><p></p>
<h2>5.3 <span class="Italics">Clostridium difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</h2>
<p class="First"><span class="Italics">Clostridium difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including cefazolin, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile.</span></p>
<p><span class="Italics">C. difficile</span> produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing isolates of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
</p>
<p>If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-6.4"></a><p></p>
<h2>5.4 Risk of Development of Drug-resistant Bacteria
</h2>
<p class="First">Prescribing Cefazolin for Injection in the absence of proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
</p>
<p>As with other antimicrobials, prolonged use of Cefazolin for Injection may result in overgrowth of nonsusceptible microorganisms. Repeated evaluation of the patient's condition is essential. Should <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occur during therapy, appropriate measures should be taken.
</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="s31"></a><a name="section-6.5"></a><p></p>
<h2>5.5 Drug/Laboratory Test Interactions
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-6.5.1"></a><p></p>
<p class="First"><span class="Italics Underline">Urinary Glucose</span></p>
<p>The administration of cefazolin may result in a false-positive reaction with glucose in the urine when using CLINITEST® tablets. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (e.g., CLINISTIX®) be used.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-6.5.2"></a><p></p>
<p class="First"><span class="Italics Underline">Coombs' Test</span></p>
<p>Positive direct Coombs' tests have been reported during treatment with cefazolin. In hematologic studies or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombs' testing of newborns whose mothers have received cephalosporin antibacterial drugs before parturition, it should be recognized that a positive Coombs' test may be due to the drug.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s34"></a><a name="section-7"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<p class="First">The following serious adverse reactions to cefazolin are described below and elsewhere in the labeling:
</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> <span class="Italics">[see Warnings and Precautions (<a href="#s27">5.1</a>)]</span>
</li>
<li>
<span class="Italics">Clostridium difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> <span class="Italics">[see Warnings and Precautions (<a href="#s29">5.3</a>)]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-7.1"></a><p></p>
<h2>6.1 Clinical Trials Experience
</h2>
<p class="First">The following adverse reactions were reported from clinical trials:
</p>
<p>Gastrointestinal: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral candidiasis</span> (<span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral thrush</span>), <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulcers</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="4091513" conceptname="Passing flatus">flatus</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> and <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>. Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibacterial treatment <span class="Italics">[see Warnings and Precautions (<a href="#s29">5.3</a>)]</span>.
</p>
<p>Allergic: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>.
</p>
<p>Hematologic: <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocythemia</span>.
</p>
<p>Hepatic: Transient rise in <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, SGPT, and alkaline phosphatase levels has been observed. As with other cephalosporins, reports of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> have been received.
</p>
<p>Renal: As with other cephalosporins, reports of increased BUN and creatinine levels, as well as <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, have been received.
</p>
<p>Local Reactions: Instances of <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> have been reported at site of injection. Some <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> has occurred.
</p>
<p>Other Reactions: <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> (including genital, vulvar and anal <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, genital <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>, and <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>). <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-7.2"></a><p></p>
<h2>6.2 Cephalosporin-class Adverse Reactions
</h2>
<p class="First">In addition to the adverse reactions listed above that have been observed in patients treated with cefazolin, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibacterials: <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> including <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, and <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s37"></a><a name="section-8"></a><p></p>
<h1>7 DRUG INTERACTIONS
</h1>
<p class="First">Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.
</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s38"></a><a name="section-9"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s39"></a><a name="section-9.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-9.1.1"></a><p></p>
<p class="First"><span class="Italics Underline">Pregnancy Category B</span></p>
<p>Reproduction studies have been performed in rats, mice and rabbits at doses of 2000, 4000 and 240 mg/kg/day or 1 to 3 times the maximum recommended human dose on a body surface area basis. There was no evidence of impaired fertility or harm to the fetus due to cefazolin.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s41"></a><a name="section-9.2"></a><p></p>
<h2>8.2 Labor and Delivery
</h2>
<p class="First">When cefazolin has been administered prior to caesarean section, drug concentrations in cord blood have been approximately one quarter to one third of maternal drug levels. The drug appears to have no adverse effect on the fetus.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s42"></a><a name="section-9.3"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">Cefazolin is present in very low concentrations in the milk of nursing mothers. Caution should be exercised when Cefazolin for Injection is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s43"></a><a name="section-9.4"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">Safety and effectiveness for use in premature infants and neonates have not been established. See <span class="Italics">Dosage and Administration (<a href="#s16">2.4</a>)</span> for recommended dosage in pediatric patients older than 1 month.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s44"></a><a name="section-9.5"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">Of the 920 subjects who received cefazolin in clinical studies, 313 (34%) were 65 years and over, while 138 (15%) were 75 years and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function <span class="Italics">[see Dosage and Administration (<a href="#s15">2.3</a>) and Warnings and Precautions (<a href="#s28">5.2</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-9.6"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">When Cefazolin for Injection is administered to patients with low urinary output because of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (creatinine clearance less than 55 mL/min.), lower daily dosage is required <span class="Italics">[see Dosage and Administration (<a href="#s15">2.3</a>) and Warnings and Precautions (<a href="#s28">5.2</a>)]</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s46"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">Cefazolin for Injection, USP is a semi-synthetic cephalosporin for parenteral administration. It is the sodium salt of 3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]-methyl}-8-oxo-7-[2-(1H-tetrazol-1-yl)acetamido]-5-thia-1-azabicyclo [4.2.0]oct-2-ene-2-carboxylic acid.
</p>
<p>Cefazolin sodium USP has the following structural formula:
</p>
<p><a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d3fe1e18-9e3e-4797-9fb4-275900fa9ff3&amp;name=cef0o-0000-01.jpg"></p>
<p>C<span class="Sub">14</span>H<span class="Sub">13</span>N<span class="Sub">8</span>NaO<span class="Sub">4</span>S<span class="Sub">3</span>                         M.W. 476.5
</p>
<p>The pH of the reconstituted solution is between 4 and 6.
</p>
<p>Cefazolin for Injection, USP is a white to cream sterile powder. The color of Cefazolin for Injection, USP solutions may range from <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow to yellow without a change in potency.
</p>
<p>Cefazolin for Injection, USP is supplied in 10 grams Pharmacy Bulk Package. Each Pharmacy Bulk Package contains cefazolin sodium equivalent to 10 grams of cefazolin. The sodium content is approximately 48 mg (2.1 mEq) per gram of cefazolin sodium.
</p>
<p>It is to be administered by intravenous route.
</p>
<p>A Pharmacy Bulk Package is a container of a sterile preparation for intravenous use that contains many single doses. The contents are intended for use in a pharmacy admixture service and are restricted to the preparation of admixtures for intravenous infusion. FURTHER DILUTION IS REQUIRED BEFORE USE.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s47"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s48"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">Cefazolin is an antibacterial drug <span class="Italics">[see Microbiology (<a href="#s51">12.4</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s49"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics
</h2>
<p class="First">The pharmacokinetic/pharmacodynamic relationship for cefazolin has not been evaluated in patients.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s50"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<p class="First">Studies have shown that following intravenous administration of cefazolin to normal volunteers, mean serum concentrations peaked at approximately 185 mcg/mL and were approximately 4 mcg/mL at 8 hours for a 1 gram dose.
</p>
<p>The serum half-life for cefazolin is approximately 1.8 hours following IV administration.
</p>
<p>In a study, using normal volunteers, of constant intravenous infusion with dosages of 3.5 mg/kg for 1 hour (approximately 250 mg) and 1.5 mg/kg the next 2 hours (approximately 100 mg), cefazolin produced a steady serum concentration at the third hour of approximately 28 mcg/mL.
</p>
<p>Studies in patients hospitalized with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> indicate that cefazolin produces mean peak serum concentrations approximately equivalent to those seen in normal volunteers.
</p>
<p>Bile concentrations in patients without obstructive biliary disease can reach or exceed serum concentrations by up to five times; however, in patients with obstructive biliary disease, bile concentrations of cefazolin are considerably lower than serum concentrations (less than 1 mcg/mL).
</p>
<p>In synovial fluid, the cefazolin concentration becomes comparable to that reached in serum at about 4 hours after drug administration.
</p>
<p>Studies of cord blood show prompt transfer of cefazolin across the placenta. Cefazolin is present in very low concentrations in the milk of nursing mothers.
</p>
<p>Cefazolin is excreted unchanged in the urine. In the first 6 hours approximately 60% of the drug is excreted in the urine and this increases to 70% to 80% within 24 hours.
</p>
<p>In patients undergoing peritoneal dialysis (2 L/hr.), cefazolin produced mean serum levels of approximately 10 and 30 mcg/mL after 24 hours' instillation of a dialyzing solution containing 50 mg/L and 150 mg/L, respectively. Mean peak levels were 29 mcg/mL (range 13 to 44 mcg/mL) with 50 mg/L (3 patients), and 72 mcg/mL (range 26 to142 mcg/mL) with 150 mg/L (6 patients). Intraperitoneal administration of cefazolin is usually well tolerated.
</p>
<p>Controlled studies on adult normal volunteers, receiving 1 gram 4 times a day for 10 days, monitoring CBC, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, SGPT, bilirubin, alkaline phosphatase, BUN, creatinine, and urinalysis, indicated no clinically significant changes attributed to cefazolin.
</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="s51"></a><a name="section-11.4"></a><p></p>
<h2>12.4 Microbiology
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-11.4.1"></a><p></p>
<p class="First"><span class="Italics Underline">Mechanism of Action</span></p>
<p>Cefazolin is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-11.4.2"></a><p></p>
<p class="First"><span class="Italics Underline">Mechanism of Resistance</span></p>
<p>Predominant mechanisms of <span class="product-label-link" type="condition" conceptid="4207042" conceptname="Viral resistance">bacterial resistance</span> to cephalosporins include the presence of extended-spectrum beta-lactamases and enzymatic hydrolysis.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-11.4.3"></a><p></p>
<p class="First"><span class="Italics Underline">Lists of Microorganisms</span></p>
<p>Cefazolin has been shown to be active against most isolates of the following microorganisms, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Italics">INDICATIONS AND USAGE (<a href="#s2">1</a>)</span> section.
</p>
<ul class="Disc"><li>Gram-Positive Bacteria<dl class="Disc">
<dt> 
</dt>
<dd><span class="Italics">Staphylococcus aureus</span></dd>
<dt> 
</dt>
<dd><span class="Italics">Staphylococcus epidermidis</span></dd>
<dt> 
</dt>
<dd><span class="Italics">Streptococcus pyogenes, and Streptococcus agalactiae</span></dd>
<dt> 
</dt>
<dd><span class="Italics">Streptococcus pneumoniae</span></dd>
</dl>
</li></ul>
<p>Methicillin-resistant staphylococci are uniformly resistant to cefazolin.
</p>
<ul class="Disc"><li>Gram-Negative Bacteria<dl class="Disc">
<dt> 
</dt>
<dd><span class="Italics">Escherichia coli</span></dd>
<dt> 
</dt>
<dd><span class="Italics">Proteus mirabilis</span></dd>
</dl>
</li></ul>
<p>Most isolates of indole positive Proteus (<span class="Italics">Proteus vulgaris</span>), <span class="Italics">Enterobacter</span> spp., <span class="Italics">Morganella morganii, Providencia rettgeri, Serratia</span> spp., and <span class="Italics">Pseudomonas</span> spp. are resistant to cefazolin.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-11.4.4"></a><p></p>
<p class="First"><span class="Italics Underline">Susceptibility Test Methods</span></p>
<p>When available, the clinical microbiology laboratory should provide the results of <span class="Italics">in vitro</span> susceptibility test results for antimicrobial drug products used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug product for treatment.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-11.4.4.1"></a><p></p>
<p class="First"><span class="Italics">Dilution Techniques</span></p>
<p>Quantitative methods are used to determine <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standard test<span class="Sup">1, 2</span> (broth and/or agar). The MIC values obtained should be interpreted according to criteria as provided in <a href="#t3">Table 3</a>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s57"></a><a name="section-11.4.4.2"></a><p></p>
<p class="First"><span class="Italics">Diffusion Techniques</span></p>
<p>Quantitative methods that require measurement of zone diameters provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be interpreted using a standard test method<span class="Sup">2, 3</span>. This procedure uses paper disks impregnated with 30 mcg cefazolin to test the susceptibility of microorganisms to cefazolin. The disk diffusion interpretive criteria are provided in <a href="#t3">Table 3</a>.
</p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3: Susceptibility Test Interpretive Criteria for Cefazolin<span class="Sup">a</span></span></caption>
<col align="left" width="21.163%">
<col align="left" width="13.804%">
<col align="left" width="13.804%">
<col align="left" width="13.647%">
<col align="left" width="11.503%">
<col align="left" width="13.032%">
<col align="left" width="13.047%">
<tfoot>
<tr class="First"><td align="left" colspan="7" valign="top"><p class="First Footnote">Abbreviations: S= susceptible, I= intermediate, R= resistant
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">a</span>Interpretive criteria are based on 1 g every 8 hr
</p></td></tr>
<tr class="Last"><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">b</span>The cefazolin disk should not be used for determining susceptibility to other cephalosporins
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="middle"><span class="Bold">Pathogen</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="middle">
<span class="Bold">Minimum Inhibitory</span><br><span class="Bold">Concentration
</span><span class="Bold">(mcg/mL)</span>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="middle">
<span class="Bold">Disk Diffusion Zone</span><br><span class="Bold">Diameter (mm)</span><span class="Bold"><span class="Sup">b</span></span>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle">S
</td>
<td class="Botrule Rrule" align="center" valign="middle">I
</td>
<td class="Botrule Rrule" align="center" valign="middle">R
</td>
<td class="Botrule Rrule" align="center" valign="middle">S
</td>
<td class="Botrule Rrule" align="center" valign="middle">I
</td>
<td class="Botrule Rrule" align="center" valign="middle">R
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<span class="Italics">Escherichia coli</span><br><span class="Italics">Proteus mirabilis</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">≤ 1
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">≥ 4
</td>
<td class="Botrule Rrule" align="center" valign="middle">-
</td>
<td class="Botrule Rrule" align="center" valign="middle">-
</td>
<td class="Botrule Rrule" align="center" valign="middle">-
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Italics">Staphylococcus aureus</span></td>
<td class="Botrule Rrule" align="center" valign="middle">≤ 8
</td>
<td class="Botrule Rrule" align="center" valign="middle">16
</td>
<td class="Botrule Rrule" align="center" valign="middle">≥ 32
</td>
<td class="Botrule Rrule" align="center" valign="middle">≥ 18
</td>
<td class="Botrule Rrule" align="center" valign="middle">15 to 17
</td>
<td class="Botrule Rrule" align="center" valign="middle">≤ 14
</td>
</tr>
</tbody>
</table>
<p>NOTE:
</p>
<p><span class="Italics">S. pyogenes</span> and <span class="Italics">S. agalactiae</span> that have a penicillin MIC of ≤ 0.12 mcg/mL, or disk diffusion zone diameters of ≥ 24 mm with a 10 mcg penicillin disk, may be interpreted as susceptible to cefazolin. <span class="Bold">Non-<span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> isolates</span> of <span class="Italics">S. pneumoniae</span> that have a penicillin MIC of ≤ 0.06 mcg/mL, may be interpreted as susceptible to cefazolin.
</p>
<p>A report of <span class="Italics">Susceptible</span> indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site necessary to inhibit growth of the pathogen. A report of <span class="Italics">Intermediate</span> indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug product is physiologically concentrated or in situations where a high dosage of the drug product can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of <span class="Italics">Resistant</span> indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site; other therapy should be selected.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s58"></a><a name="section-11.4.5"></a><p></p>
<p class="First"><span class="Italics Underline">Quality Control</span></p>
<p>Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individual performing the test<span class="Sup">1, 2, 3</span>. Standard cefazolin powder should provide the following MIC values noted in <a href="#t4">Table 4</a>. For the diffusion technique using the 30 mcg disk, the criteria in <a href="#t4">Table 4</a> should be achieved.
</p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4: Acceptable Quality Control Ranges for Cefazolin
</span></caption>
<col align="left" width="29.133%">
<col align="left" width="35.033%">
<col align="left" width="35.833%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">QC Isolate
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentration</span> mcg/mL
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">Disk Diffusion<br>Zone Diameters (mm)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<span class="Italics">E. coli</span> ATCC<span class="Sup">®</span> 25922
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 to 4
</td>
<td class="Botrule Rrule" align="center" valign="middle">21 to 27
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<span class="Italics">S. aureus</span> ATCC<span class="Sup">®</span> 29213
</td>
<td class="Botrule Rrule" align="center" valign="middle">0.25 to 1
</td>
<td class="Botrule Rrule" align="center" valign="middle">------------
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<span class="Italics">S. aureus</span> ATCC<span class="Sup">®</span> 25923
</td>
<td class="Botrule Rrule" align="center" valign="middle">-------------
</td>
<td class="Botrule Rrule" align="center" valign="middle">29 to 35
</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s59"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s60"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Mutagenicity studies and long-term studies in animals to determine the carcinogenic potential of Cefazolin for Injection have not been performed.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s61"></a><a name="section-13"></a><p></p>
<h1>15 REFERENCES
</h1>
<ol class="Arabic">
<li>Clinical Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically</span>; Approved Standard-Ninth Edition. CLSI Document M07-A9. CLSI, 940 West Valley Road, Suite 2500, Wayne, PA, 2012.
</li>
<li>Clinical Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing</span>; Twentieth Informational Supplement. CLSI document M100-S20. CLSI, Wayne, PA, 2010.
</li>
<li>Clinical Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Disk Susceptibility Tests</span>; Approved Standard-Eleventh Edition. CLSI Document M02-A11. CLSI, Wayne, PA, 2012.
</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s62"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">Each Pharmacy Bulk Package contains cefazolin sodium equivalent to 10 grams of cefazolin.
</p>
<table width="100%">
<col align="left" width="23.000%">
<col align="left" width="43.667%">
<col align="left" width="33.333%">
<tbody class="Headless">
<tr class="First">
<td align="justify" valign="top"><span class="Bold">NDC</span></td>
<td align="justify" valign="top"><span class="Bold">Cefazolin for Injection, USP</span></td>
<td align="justify" valign="top"><span class="Bold">Package Factor</span></td>
</tr>
<tr>
<td align="justify" valign="top">25021-102-69
</td>
<td align="justify" valign="top">Cefazolin sodium equivalent
</td>
<td align="justify" valign="top">10 Pharmacy Bulk
</td>
</tr>
<tr class="Last">
<td align="justify" valign="top"></td>
<td align="justify" valign="top">to 10 grams of cefazolin
</td>
<td align="justify" valign="top">Packages per carton
</td>
</tr>
</tbody>
</table>
<p>Cefazolin for Injection, USP, containing cefazolin sodium equivalent to 500 mg or 1 gram of cefazolin, is also available as follows:
</p>
<table width="100%">
<col align="left" width="22.100%">
<col align="left" width="44.567%">
<col align="left" width="33.333%">
<tbody class="Headless">
<tr class="First">
<td align="justify" valign="top"><span class="Bold">NDC</span></td>
<td align="justify" valign="top"><span class="Bold">Cefazolin for Injection, USP</span></td>
<td align="justify" valign="top"><span class="Bold">Package Factor</span></td>
</tr>
<tr>
<td align="justify" valign="top">25021-100-66
</td>
<td align="justify" valign="top">Cefazolin sodium equivalent to
</td>
<td align="justify" valign="top">25 vials per carton
</td>
</tr>
<tr>
<td align="justify" valign="top"></td>
<td align="justify" valign="top">500 mg cefazolin
</td>
<td align="justify" valign="top"></td>
</tr>
<tr>
<td align="justify" valign="top">25021-101-67
</td>
<td align="justify" valign="top">Cefazolin sodium equivalent to
</td>
<td align="justify" valign="top">25 vials per carton
</td>
</tr>
<tr class="Last">
<td align="justify" valign="top"></td>
<td align="justify" valign="top">1 gram cefazolin
</td>
<td align="justify" valign="top"></td>
</tr>
</tbody>
</table>
<p>As with other cephalosporins, reconstituted Cefazolin for Injection, USP tends to darken depending on storage conditions, within the stated recommendations. However, product potency is not adversely affected.
</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s63"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Storage Statement</span></p>
<p>Before reconstitution, store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] <span class="Bold">Protect from light</span>.
</p>
<p><span class="Bold">Sterile, Nonpyrogenic, Preservative-free.</span></p>
<p><span class="Bold">The container closure is not made with natural rubber latex.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s64"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First">Patients should be advised that <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, including serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> could occur and that serious reactions require immediate treatment and discontinuation of cefazolin. Patients should report to their health care provider any previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to cefazolin, cephalosporins, penicillins, or other similar antibacterials.
</p>
<p>Patients should be advised that <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> is a common problem caused by antibiotics, which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibacterials. If this occurs, patients should contact a physician as soon as possible.
</p>
<p>Patients should be counseled that antibacterial drugs, including Cefazolin for Injection should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When Cefazolin for Injection is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Cefazolin for Injection or other antibacterial drugs in the future.
</p>
<p>Rx only
</p>
<p>ATCC is a registered trademark of American Type Culture Collection.<br>CLINITEST is a registered trademark of Siemens Medical Solutions Diagnostics.<br>CLINISTIX is a registered trademark of Bayer Healthcare LLC.
</p>
<p><span class="Bold">PREMIER</span>ProRx™<br>Mfd. for SAGENT Pharmaceuticals<br>Schaumburg, IL 60195 (USA)<br>Made in Italy<br>©2015 Sagent Pharmaceuticals, Inc.
</p>
<p>PREMIERProRx™ is a trademark of Premier, Inc., used under license.
</p>
<p>Revised: February 2015
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s65"></a><a name="section-16"></a><p></p>
<p class="First">PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Bottle Label
</p>
<p>NDC 25021-102-69
</p>
<p>Cefazolin for Injection, USP
</p>
<p>PHARMACY BULK PACKAGE
</p>
<p>NOT FOR DIRECT INFUSION
</p>
<p>10 grams
</p>
<p>Per Pharmacy Bulk Package
</p>
<p>NOT TO BE DISPENSED AS A UNIT
</p>
<p>FURTHER DILUTION IS REQUIRED
</p>
<p>Rx only
</p>
<p>For Intravenous Use
</p>
<div class="Figure">
<a name="f02"></a><img alt="PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Bottle Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d3fe1e18-9e3e-4797-9fb4-275900fa9ff3&amp;name=cef0o-0000-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFAZOLIN 		
					</strong><br><span class="contentTableReg">cefazolin sodium injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:25021-102</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>cefazolin sodium</strong> (cefazolin) </td>
<td class="formItem">cefazolin</td>
<td class="formItem">10 g</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:25021-102-69</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065306</td>
<td class="formItem">07/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sagent Pharmaceuticals
							(796852890)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6bd85dfb-a822-4221-93c6-3ddaf1dfbedb</div>
<div>Set id: d3fe1e18-9e3e-4797-9fb4-275900fa9ff3</div>
<div>Version: 2</div>
<div>Effective Time: 20150215</div>
</div>
</div> <div class="DistributorName">Sagent Pharmaceuticals</div></p>
</body></html>
